RESEARCH ARTICLE

THE EFFECT OF IRON AND ERYTHROPOIETIN TREATMENT ON THE HBA1C OF HEMODIALYSIS PATIENTS WITH DIABETES.

Ayman M. El-Badawy, Mohamed Yehia Seddek and Mohamed Shawky El-sayed Samira Marawan Hassan.
Internal medicine department, Faculty of medicine, Banha University, Qalyubia, Egypt.

Abstract

Background & Aims: The aim of this thesis is to validate the effect of iron and erythropoietin treatment on the HbA1c of hemodialysis patients with diabetes.

Methods: This study was conducted on 50 HD patients with type-2 diabetes. All patients were selected from those undergoing regular HD in nephrology and dialysis unit in Banha University Hospitals. The diagnosis of diabetes will be based on a history of diabetes or on the ADA criteria. The patients will be classified into two groups (each consists of 25 patients). The first group (group A) are patients selected for iron therapy according to clinical need. The second group (group B) consisted of patients who were those needing ESA treatment. Glycemic control in both patient groups will be assessed using HbA1c in the month leading up to treatment and once again for a 4-week period 4 months after therapy. The main values of the three-monthly measurements of casual.

Results: A1C value falls after four months of therapy in both groups (iron and ESA group) compared to before therapy. This change was independent on glycemic control.

Conclusions: A1C is the most widely accepted and used method of assessing chronic glycemia in patients with diabetes. This is study showed that iron and ESA treatments result in a fall in A1C, which is independent of glycemic changes in patients with diabetes and CKD.

Introduction:

A1C is the most widely accepted and used method of assessing chronic glycemia in patients with diabetes. It is formed by the irreversible binding of glucose to hemoglobin over the lifespan of the erythrocytes (Goldstien et al, 2004). Patients with Chronic kidney disease (CKD) are commonly anemic due to a variety of reasons, including functional or absolute iron deficiency and erythropoietin insufficiency. Treatment of anemia in patients with CKD using iron replacement therapy and erythropoietin-stimulating agents (ESAs) has resulted in significant improvements to quality of life and the correction of anemia without the need for blood transfusions (Nissenson et al, 1999).
Material and Methods:

This study was conducted on 50 HD patients with type-2 diabetes. All patients were selected from those undergoing regular HD in nephrology and dialysis unit in Banha University Hospitals. The diagnosis of diabetes was based on a history of diabetes or on the ADA criteria. Information collected from participants included demographic data, height, weight (dry weight in HD patients), duration of diabetes and duration of HD.

Inclusion criteria: Patients with type 2 DM who fulfill the following criteria; regular HD, anemia due to CKD. Patients with diabetes were restricted to those with stable blood glucose and whose diabetes treatment had not been altered during the preceding 6 months before the determination of HbA1c.

Exclusion criteria: Patients with hemoglobinopathy, anemia due to causes other than CKD, patients who had a history of overt blood loss or who received a blood transfusion 4 months prior to the study, patients with evidence of scurvy, evidence of hepatic disorders, inflammatory disease or thyroid disease, who had been previously treated with ESA on renal replacements, or with previous transplantation were excluded from the study. The patients will be classified into two groups (each consists of 25 patients). The first group (group A): serum ferritin values <200 µg/l these patients were candidate for iron therapy. The second group (group B): serum ferritin value >200 µg/l these patients were candidate for ESA therapy. Glycemic control in both patient groups was assessed using HbA1c in the month leading up to treatment and once again for a 4-week period 4 months after therapy. Blood was drawn without overnight fasting, immediately before the session of HD. Blood was drawn from the dialyzer circuit prior to the initiation of dialysis or administration of anticoagulants. Blood samples were divided into 5 ml sent for HbA1c and 5 ml centrifuged with the serum frozen at 80 °C for measurement of GA, 8 ml will be analyzed for total protein, albumin, blood urea nitrogen and creatinine and 2 ml on EDTA for CBC. All the patients selected for iron therapy had either absolute or functional iron deficiency as evidenced by serum ferritin values <200 µg/l. All patients had hemoglobin ≤ 10.5 g/dl. Patients in this group were not on previous or concurrent ESA therapy and were vitamin B12 and folate replete. Intravenous iron was given as a single dose in the form of low-molecular-weight iron dextran dependent on the patient’s body weight. This will delivered as an initial intravenous test infusion of 100 mg of iron over 1 h followed by the remaining dose over the next 2-4 h. All patients receiving ESA therapy had hemoglobin < or =10.5 g/dl and were considered iron, vitamin B12, and folate replete prior to initiation. Patients were considered iron replete following a serum ferritin value >200 µg/l or having received intravenous iron at least 6 weeks prior to ESA therapy. The dose of ESA will be titrated monthly to achieve target hemoglobin 10.5-12 g/dl.

Statistical analysis:
The collected data were tabulated and analyzed using SPSS version 16 software (SpssInc, Chicago, ILL Company) and. Categorical data were presented as number and percentages while quantitative data were expressed as mean ± standard deviation, and range. Categorical variables were analyzed using Chi square test (X2) and Fisher’s exact test (FET). Quantitative data were tested for normality using Shapiro- Wilks test, assuming normality at P >0.05. St.”t test was used to analyze the difference between 2 independent groups regarding normal variables, non parametric variables were analyzed using Mann Whitney U test (MWU) for 2 independent groups and Friedman test which was used to test the differences between matched variables considering P value significant at 0.05. Significant Friedman test was followed by post hoc multiple comparisons using Bonferroni adjusted Wilcoxon test to detect the significant pairs at adjusted P =0.017

Results:

Table 1: Socio-demographic characters of the studied groups.

| Variable      | No. (n=50) | % (100.0) |
|---------------|------------|-----------|
| Group A       | 25         | 50.0      |
| Group B       | 25         | 50.0      |
| Sex           |            |           |
| Male          | 22         | 44.0      |
| Female        | 28         | 56.0      |
| Age (ys)      | 56.3 ±5.7  | 40-65     |
50 studied patient group (A):25 patients and Group(B):25 patients Among 50 studied patient 22 patients were male, 28 patients were female Mean age(ys):56.3 of range from 40 to 65 years Mean weight(kg):79.8 of range from 56 to 110 kg Mean height (cm):162.2 of range from150 to 175 cm Mean bmi(kg/m):30.07 of range from 23.2 to 40.2 kg/m

| Variable       | Group A (N=25) | Group B (N=25) | Test of significance | P     |
|----------------|----------------|----------------|----------------------|-------|
| Sex            |                |                |                      |       |
| Male           | 8              | 14             | X²=                  | 0.09  |
| Female         | 17             | 11             |                      | (NS)  |
| Age (ys)       | Mean ± SD (Range) | 57.1±3.2 (52-60) | 55.6±7.4 (40-65) | St."t"= | 0.34 |
| Weight (kg)    | Mean ± SD (Range) | 75.4±17.4 (56-103) | 84.0±17.5 (60-110) | St."t"= | 0.09 |
| Height (cm)    | Mean ± SD (Range) | 159.8±6.2 (152-170) | 161.2±9.6 (150-175) | St."t"= | 0.55 |
| BMI (kg/m²)    | Mean ± SD (Range) | 29.4±5.9 (23.2-40.2) | 30.7±5.1 (25.0-36.75) | St."t"= | 0.34 |

Among studied groups Group A formed from 8 male and 17 female patients Group B formed from 14 male and 11 female patients in group A mean age 57.1 and in groupB mean age 55.6 which statistically non significant ( p=.34) in group A mean weight was 75.4 and in groupB mean weight was 84 which statistically non significant ( p=.09) in group A mean height was 159.8 and in groupB mean height was 161.2 which statistically non significant ( p=.55) in group A mean BMI was 29.4 and in groupB mean BMI was 30.7 which statistically non significant ( p=.34)
Table 3:- Comparison of the studied groups regarding duration of DM and hemodialysis.

| Variable          | Group A (N=25) | Group B (N=25) | St. ’t’  | P     |
|-------------------|----------------|----------------|----------|-------|
|                   | Mean ± SD | Range  | Mean ± SD | Range |       |       |
| Duration of DM (ys) | 14.52   | 5.12  | 10-25   | 12.92 | 5.75 | 4-25  | 1.04   | 0.3 (NS) |
| Duration of HD (ys) | 3.48  | 2.44  | 1-8     | 2.84  | 1.69 | 1-6   | 1.08   | 0.28 (NS) |

Among studied groups:
In group A mean duration of DM was 14.52 and in group B mean duration of DM was 12.92 which statistically non significant( p=.3)

In group A mean duration of HD was 3.48 and in group B mean duration of HD was 2.84 which statistically non significant( p=.28)

![Duration of DM and HD among groups](image)

Table 4:- Comparison of the studied groups regarding type of treatment.

| Group | TTT | Life style, diet |
|-------|-----|------------------|
|       | Premix insulin | Count | 13 | 11 | 24 |
|       | % within Group  | 52.0% | 44.0% | 48.0% |
|       | Life style, diet | Count | 12 | 14 | 8 |
|       | % within Group  | 48.0% | 56.0% | 16.0% |
|       | Total | Count | 25 | 25 | 50 |
|       | % within Group  | 100.0% | 100.0% | 100.0% |

FET was used P=0.81 (NS)

This table show regimen for glycemic control for both groups.

Table 5:- Comparison of the studied groups regarding laboratory findings before treatment.

| Variable       | Group A (N=25) | Group B (N=25) | MWU test | P     |
|----------------|----------------|----------------|----------|-------|
|                | Mean ± SD | Range  | Mean ± SD | Range |       |       |
| S. Ferritin    | 85.1   | 52.54  | 27-167.4  | 1039.9 | 607.30 | 292.5-2000 | 6.08 | <0.001 (HS) |
| HbA1C          | 6.7    | 0.64   | 6.2-8.3   | 6.42   | 0.77   | 4.5-7.1    | 0.029 | 0.98 (NS) |
| PPG            | 176.7  | 90.91  | 130-375   | 162.1  | 27.13  | 130-200    | 0.26  | 0.79 (NS) |
| T. protein     | 6.57   | 0.35   | 6.2-7.3   | 6.53   | 0.22   | 6.1-6.9    | 0.36  | 0.72 (NS) |
| Albumin        | 3.37   | 0.22   | 3.1-3.7   | 3.42   | 0.30   | 3-3.7      | 0.60  | 0.54 (NS) |
| BUN            | 125.2  | 57.99  | 26-212    | 134.1  | 36.39  | 84-197     | 0.31  | 0.76 (NS) |
| Creatinine     | 6.1    | 3.0    | 1.8-9.7   | 7.11   | 2.17   | 3.5-11.4   | 1.29  | 0.19 (NS) |
| Hb%            | 8.8    | 1.39   | 6.6-10.5  | 9.2    | 1.32   | 6.6-10.5   | 1.34  | 0.18 (NS) |
In studied groups
In group A mean serum ferritin before treatment was 85.1ng/dl compared with group B mean serum ferritin before treatment was 1039.9ng/dl which statistically highly significant (p < .001)

HA1C, PPG, T, protein, albumin, BUN, creatinine, Hb% before treatment in group A compared with group B were non significant.

**Table 6:** Comparison of serum ferritin before and after treatment among the studied groups.

| Serum ferritin | Group A (N=25) | Group B (N=25) | MWU test | P |
|----------------|----------------|----------------|-----------|---|
|                | Mean ± SD      | Min.           | Max.      | Mean ± SD | Min. | Max. |       |    |
| Before intervention | 85.18 ± 52.54 | 27.00          | 167.40    | 1039.9 ± 607.30 | 292.50 | 2000.0 | 6.08 | <0.001 (HS) |
| 1 month later   | 515.77 ± 210.68 | 320.00         | 921.00    | 885.0 ± 528.48 | 250.00 | 1650.0 | 2.38 | 0.017 (S) |
| 4 months later  | 360.73 ± 116.28 | 229.50         | 550.00    | 950.3 ± 570.58 | 245.00 | 1650.0 | 4.75 | <0.001 (HS) |
| Friedman test   | 39.1           | 31.0           |           |             |     |     |       |    |
| P               | <0.001 (HS)    | <0.001 (HS)    |           |             |     |     |       |    |
| Sig pairs       | Before ≠ 1m    | Before ≠ 1m    | Before ≠ 4m | Before ≠ 4m |

Among studied groups
In group A mean serum ferritin before treatment 85.18µg/l compared with one month later 515.77µg/l and four months later 360.73µg/l which was highly significant (p <0.001)

In group B mean serum ferritin before treatment 1039.9µg/l compared with one month later 885µg/l and four months later 950.3µg/l which was highly significant (p <0.001). In group B mean values of serum ferritin were significantly high compared with group A in whole duration of study (p <0.001).

**Fig 3:** S. ferritin among studied groups before treatment.

**Fig 4:** S. Ferritin among groups during treatment.
Table 7: Comparison of hemoglobin before and after treatment among the studied groups.

| Hb% | Group A (N=25) | Group B (N=25) | MWU test | P        |
|-----|----------------|----------------|----------|----------|
|     | Mean ± SD      | Min. Max.      | Mean ± SD | Min. Max. |              |           |
| Before intervention | 8.80 ± 1.39 | 6.6 - 10.5 | 9.26 ± 1.32 | 6.6 - 10.5 | 1.34 | 0.18 (NS) |
| 1 month later       | 10.05 ± 1.03 | 8.6 - 11.0 | 10.32 ± 0.75 | 9.0 - 11.2 | 1.21 | 0.22 (NS) |
| 4 months later      | 11.06 ± 0.75 | 10.5 - 12.7 | 11.01 ± 0.51 | 10.3 - 12.0 | 0.43 | 0.67 (NS) |

In group A mean value of Hb% before treatment 8.8% compared with one month later 10.05% and four months later 11.06% which was highly significant (p<0.001)

In group B mean value of Hb% before treatment 9.26% compared with one month later 10.32% and four months later 11.01% which was highly significant (p< 0.001)

In group B mean value of Hb% before treatment and one month later and four months later compared with that of group A was non significant.

Fig. 5: Hb% value among groups during treatment

Table 8: Comparison of fasting blood glucose before and after treatment among the studied groups.

| Fasting blood glucose | Group A (N=25) | Group B (N=25) | MWU test | P        |
|----------------------|----------------|----------------|----------|----------|
|                      | Mean ± SD  | Min. Max.      | Mean ± SD | Min. Max. |              |           |
| Before intervention  | 101.6 ± 27.5 | 80.0 - 150.0  | 90.8 ± 13.0 | 73.0 - 110.0 | 0.519 | 0.6 (NS)   |
| 1 month later        | 102.0 ± 27.1 | 81.0 - 149.0  | 95.8 ± 31.79 | 74.0 - 176.0 | 1.8  | 0.07 (NS)  |
| 4 months later       | 101.6 ± 27.6 | 80.0 - 151.0  | 90.2 ± 12.85 | 74.0 - 111.0 | 0.517 | 0.61 (NS)  |
| Friedman test        | 3.8          | 5.34           |           |           |
| P                    | 0.16 (NS)    | 0.069 (NS)     |           |           |
| Sig pairs            | ------------  | ------------   |           |           |
Table 9: Comparison of PP blood glucose before and after treatment among the studied groups.

| PP blood glucose   | Group A (N=25) | Group B (N=25) | MWU test | P         |
|--------------------|----------------|----------------|----------|-----------|
| Before intervention| Mean± SD       | Min. Max.      | Mean± SD | Min. Max. |
|                    | 176.7± 90.91   | 130.0-375.0    | 151.7± 22.59 | 130.0-200.0 |
| 1 month later      | 178.4± 81.4    | 120.0-340.0    | 146.40± 17.41 | 125.0-170.0 |
| 4 months later     | 174.1± 81.98   | 125.0-365.0    | 140.31± 12.76 | 120.0-160.0 |
| Friedman test      | 5.10           | 5.37           | 0.1 (NS) | 0.07 (NS) |
| Sig pairs          | --------       | --------       | -------- | --------  |

Fig 6: FBG among the studied groups during course of treatment.

Fig 7: PP blood glucose among studied groups.
Table 10: Comparison of HbA1C before and after intervention among the studied groups.

| HbA1C | Group A (N=25) | Group B (N=25) | MWU test | P     |
|-------|----------------|----------------|----------|-------|
|       | Mean ± SD      | Min. | Max. | Mean ± SD | Min. | Max. |       |
| Before intervention | 6.70 ± 0.64 | 6.20 | 8.30 | 6.42 ± 0.77 | 4.50 | 7.10 | 0.029 | 0.98 (NS) |
| 1 month later | 6.02 ± 0.94 | 5.00 | 8.10 | 5.61 ± 0.82 | 4.50 | 6.90 | 1.72 | 0.084 (NS) |
| 4 months later | 5.95 ± 0.76 | 5.00 | 8.00 | 5.41 ± 0.91 | 4.30 | 7.00 | 2.35 | 0.019 (S) |

Friedman test
P 0.001 (HS) <0.001 (HS)
Sig pairs Before ≠ 1m Before ≠ 4m

Among studied groups
In group A mean value of HbA1C before treatment 6.7% compared with one month later 6.02% and four months later 5.95% which was highly significant (p=0.001). In group B mean value of HbA1C before treatment 6.42 % compared with one month later 5.61% and four months later 5.41 % which was highly significant (p<0.001). In group B mean value of HbA1C before treatment and one month later compared with that of group A was non significant but four months later was significant (p=0.019)

Table 11: Correlation between HbA1c and FBG, PP blood glucose.

| With | HbA1c (before intervention) | Group A | Group B |
|------|-----------------------------|---------|---------|
|      | rho                         | P       | rho     | P     |
| FBG  | 0.242                       | 0.24 (NS)| 0.14    | 0.49 (NS) |
| PP bl glucose | 0.311                      | 0.015 (NS)| 0.329 | 0.11 (NS) |
|      | HbA1c (1 m after intervention) |         |         |
| FBG  | 0.016                       | 0.93 (NS)| 0.11    | 0.61 (NS) |
| PP bl glucose | 0.42                       | 0.84 (NS)| 0.31    | 0.16 (NS) |
|      | HbA1c (4 m after intervention) |         |         |
| FBG  | 0.07                        | 0.74 (NS)| 0.13    | 0.52 (NS) |
| PP bl glucose | 0.29                       | 0.16 (NS)| 0.21    | 0.32 (NS) |

This table showed non significant Correlation between HbA1c and FBG, PP blood glucose.

Table 12: Comparison of total protein before and after intervention among the studied groups.

| Total protein | Group A (N=25) | Group B (N=25) | MWU test | P     |
|---------------|----------------|----------------|----------|-------|
|               | Mean ± SD      | Min. | Max. | Mean ± SD | Min. | Max. |       |
| Before intervention | 6.57 ± 0.35 | 6.20 | 7.30 | 6.55 ± 0.23 | 6.10 | 6.90 | 0.36 | 0.71 (NS) |
| 1 month later | 6.71 ± 0.45 | 6.00 | 7.40 | 6.58 ± 0.22 | 6.30 | 7.00 | 1.04 | 0.29 (NS) |
Among studied groups, mean values of T. Protein in group A and group B along course of treatment were non significant.

**Fig 9** - T. Protein value among groups during treatment

**Table 13** - Comparison of albumin before and after treatment among the studied groups.

| Albumin          | Group A (N=25) | Group B (N=25) | MWU test | P     |
|------------------|----------------|----------------|----------|-------|
|                  | Mean ± SD      | Min.           | Max.     | Mean ± SD | Min. | Max. |         |       |
| Before intervention | 3.37 ± 0.22 | 3.10 | 3.7 | 3.42 ± 0.30 | 3.0  | 3.7 | 0.60 | 0.54 (NS) |
| 1 month later     | 3.53 ± 0.19 | 3.20 | 3.8 | 3.46 ± 0.28 | 3.1  | 3.9 | 1.09 | 0.27 (NS) |
| 4 months later    | 3.66 ± 0.22 | 3.40 | 4.0 | 3.53 ± 0.18 | 3.2  | 3.8 | 1.61 | 0.11 (NS) |

Friedman test 5.04 | 4.97

**Sig pairs**

Among studied groups
Mean values of albumin in group A and group B along course of treatment were non significant.
Fig.10: Albumin value among groups during treatment

Table 14: Comparison of Creatinine before and after treatment among the studied groups.

| Creatinine | Group A (N=25) | Group B (N=25) | MWU test | P       |
|------------|--------------|--------------|----------|---------|
|            | Mean ± SD    | Min. | Max. | Mean ± SD    | Min. | Max. |          |         |
| Before intervention | 6.14 ± 3.07  | 1.80 | 9.70 | 7.11 ± 2.17  | 3.50 | 11.40 | 1.29     | 0.19 (NS) |
| 1 month later | 5.91 ± 2.88  | 1.80 | 9.50 | 6.31 ± 1.85  | 3.50 | 9.50  | 0.84     | 0.41 (NS) |
| 4 months later | 7.59 ± 3.74  | 2.50 | 14.10| 6.79 ± 2.27  | 3.60 | 10.50 | 0.44     | 0.66 (NS) |
| Friedman test | 3.2          |      |     | 4.93        |      |       |          |         |
| P           | 0.19 (NS)    |      |     | 0.09 (NS)   |      |       |          |         |
| Sig pairs   | -----------  |      |     | -----------  |      |       |          |         |

Mean values of creatinine in group A and group B along course of treatment were non significant.

Fig 11: Creatinine value among groups during treatment
Table 15:- Comparison of Blood urea nitrogen before and after treatment among the studied groups.

| BUN | Group A (N=25) | Group B (N=25) | MWU test | P |
|-----|----------------|----------------|----------|---|
| Mean ± SD | Min. | Max. | Mean ± SD | Min. | Max. |
| Before intervention | 122.41 ± 43.39 | 26.0 | 212.0 | 123.21 ± 37.85 | 84.0 | 197.0 | 0.92 | 0.34 (NS) |
| 1 month later | 119.44 ± 53.48 | 40.0 | 210.0 | 117.82 ± 35.92 | 80.0 | 195.0 | 0.87 | 0.38 (NS) |
| 4 months later | 113.92 ± 48.30 | 50.0 | 200.0 | 115.00 ± 34.03 | 85.0 | 190.0 | 0.44 | 0.66 (NS) |

Friedman test | 4.63 | 3.84 |

P | 0.092 (NS) | 0.15 (NS) |

Sig pairs | -------- | -------- |

Fig 12:- BUN value among groups during treatment.

Discussion:-

A1c is the most widely accepted and used method of assessing chronic glycemia in patients with diabetes. It is formed by the irreversible binding of glucose to hemoglobin over the lifespan of the erythrocytes (Goldstien et al., 2004).

Patients with Chronic kidney disease (CKD) are commonly anemic due to a variety of reasons, including functional or absolute iron deficiency and erythropoietin insufficiency (Gotloib et al., 2006). Treatment of anemia in patients with CKD using iron replacement therapy and erythropoietin-stimulating agents (ESAs) has resulted in significant improvements to quality of life and the correction of anemia without the need for blood transfusions (NCCCCA, et al., 2006, and Nissenson et al., 1999).

ESAs and intra venous iron are commonly used therapies in the management of anemia in patients with CKD. Patients with both diabetes and CKD have a higher prevalence of severe anemia compared with patients with CKD alone (Thomas et al., 2003).

For the purpose of detecting new cases of diabetes, in those with an initial A1C <6.0%, rescreening at intervals shorter than 3 years identifies few individuals (~≤1%) with an A1C ≥6.5%. At A1C ≥6%, rescreening even at a 1-year interval would be reasonable strategy to identify disease. (Osamu et al., 2016)

One of categories of increased risk for type2 diabetes (Prediabetes ) (ADA 2016 Guidelines) was A1C equal 5.7-6.4%(39-46 mmol/mol)
The aim of this thesis was to evaluate:
The effect of iron and erythropoietin treatment on the HbA1c of hemodialysis patient with diabetes.

This study was conducted on 50 HD patients with type-2 diabetes. All patients was chosen from those attending Banha University Hospitals. The diagnosis of diabetes was based on a history of diabetes or on the ADA criteria. Information collected from participants included demographic data, height, weight (dry weight in HD patients), duration of diabetes and duration of HD. Patients with diabetes was restricted to those with stable blood glucose and whose diabetes treatment had not been altered during the preceding 6 months before the determination of HbA1c.

The patients was classified into two groups (each consists of 25 patients).
The first group (group A): It included patients selected for iron therapy with serum ferritin values <200 µg/l. All patients had hemoglobin \( \leq 10.5 \) g/dl. Patients in this group were not on previous or concurrent ESA therapy and were vitamin B12 and folate replete. Intravenous iron was given as a single dose in the form of low-molecular weight iron dextran dependent on the patient's body weight. This was delivered as an initial intravenous test infusion of 100 mg of iron over 1 h followed by the remaining dose over the next 2-4 h.

The second group (group B): It consisted of patients who needed ESA treatment with serum ferritin value >200 µg/l. All patients receiving ESA therapy had hemoglobin \( < \) or \( =10.5 \) g/dl and were considered iron, vitamin B12, and folate replete prior to initiation. Patients were considered iron replete following a serum ferritin value \( >200 \) µg/l or having received intravenous iron at least 6 weeks prior to ESA therapy. The dose of ESA was titrated monthly to achieve target hemoglobin 10.5-12 g/dl.

All patients were subjected to complete history taking (age, sex, type of diabetes, medications and duration of HD), complete physical examination investigated for HbA1c, random blood glucose, S.Ferretin, T.Protein, albumin, BUN, creatinine before treatment, one month later and four month later.

The result of this work were tabulated and statistically analysed using suitable statistical tests. The results of this study were that, in group A patients, parental iron administration was attended with a significant rise of serum ferretin after four months. In group B, serum ferretin showed a significant fall four months after ESA therapy. Table(6)Fig(4).

In this study, there was significant improvement in haemoglobin level in both groups (in group A mean hemoglobin after four months 11.06% compared with before therapy8.85% (p<0.001), in group B mean hemoglobin after four months 11.01% compared with before therapy 9.26% (p<0.001)) with treatment and a decrease in the number of patients requiring blood transfusions. Table(7)Fig(5).

The other results came in coordination with, Thomas et al., 2003 who reported that anemia of CKD was improved by ESAs and intra venous iron, Muñoz et al., 2008 who reported that administration of ESAs and iron managed the anemia of CKD and achieved target haemoglobin level, and Lucia et al., 2016 who reported that anemia in CKD was managed primary with ESAs and iron therapy.

In our study, the dose of ESA was titrated monthly to achieve target hemoglobin of 10.5-12 gm/dl and this resulted in correction of anemia and improvement of quality of life. In agreement with our study, several studies have demonstrated that the correction of anemia in patients with chronic kidney disease improves the quality of life and exercise tolerance while reducing the need for transfusion. Al-Khoury et al., 2007, Teehan, 1991

The 2006 NKF KDOQI-recommended target Hb concentration is >11-12 g/dl, with recommendations against routinely maintaining Hb concentrations of >13 g/dl in patients with CKD (National Kidney Foundation, 2006).

On the other hand, the CHOIR trial studied the outcomes of anemia treatment in over 1400 CKD patients who had a hemoglobin <11 g/dl at entry. Enrolled subjects were randomly assigned to EPO therapy treatment protocols designed to achieve a target hemoglobin levels of either 13.5 (n=715) or 11.3 g/dl (n= 717). The study was terminated prematurely due to higher mortality rates adverse events in the group with higher targeted Hb levels (Singh et al., 2006), (Teearhan and Benz., 2011).

Pfeffer et al., 2009 reported that despite the increased usage of ESA agents, his findings had shown that the correction of anemia to levels of hemoglobin in excess of 12.5 g/dl in patients with type 2 diabetes using this therapy had not led to an improvement in mortality but rather an increased risk of stroke. This study showed that iron and...
ESA treatments result in a significant fall in A1C in patients with diabetes and CKD, the change was independent of glycemic changes. Table (11). In group A mean value of HbA1C before treatment was 6.7% compared with HbA1C four months after which was 5.95%. In group B the mean value of HbA1C before treatment was 6.42% whereas HbA1C after four months was 5.41%. Table (10) Fig (8). This study showed no significant change occur in fasting and post prandial levels among groups during course of treatment. Table (8,9) Fig (6,7). This study showed non significant Correlation between HbA1C and FBG, PP blood glucose among groups during the course of the study. Table (11). This results came in coordination with (Sunil et al., 2010) who achieved a similar study and reported that despite a lack of change of glycemic control in the both groups, A1C concentrations fell significantly (P<0.001 and 0.013, respectively, for groups A and B). The effect of the lowering of the A1c values following either treatment has been postulated to be secondary to the formation of new erythrocytes in the blood stream, causing a change of proportion of young to old cells, and also from an alteration in the red-cell glycation rates (Brooks et al., 1980, and Kim et al., 2006). Discordantly high A1C values compared with glucose readings have been reported in previous studies and case reports on non diabetic patients with iron deficiency and in patients with type 1 diabetes in childhood and pregnancy (Hashimoto, 2008, Brooks et al., 1980, and Kim et al., 2006). Hemolytic anemia as well as recovery from acute blood loss seem to have the opposite effect to iron deficiency by reducing HbA1c in affected individuals. Reports have shown that abnormally low HbA1c levels may be associated to conditions such as hereditary spherocytosis, elliptocytosis, autoimmune or drug-induced hemolytic anemia, and anemia due to chronic renal failure. These conditions are characterized by reduced red cell survival and therefore by a reduction in the availability of hemoglobin for glycation (Jiao et al., 1998, Herranz et al., 1999, Liew and Cheah, 2003, Kutter and Thoma, 2006 and Lum, 2010). High levels of urea in the blood can lead to formation of carbamylated hemoglobin that can interfere with some methods of HbA1c measurement. However, carbamylated hemoglobin does not present an analytical interference in most modern methods of measurement (Weykamp et al., 1993). The correction of the iron deficiency in all patient groups leaded to a significant fall in A1c values in our study.

Several studies have also shown a fall in A1C concentrations following ESA treatment in patients with diabetes undergoing hemodialysis (Inaba et al., 2007, Nakao et al., 1998). (Nakao et al., 1998) reported a fall in A1C in non diabetic patients with CKD on hemodialysis following ESA therapy.

Good glycemic control in patients with diabetes and CKD has been shown to be associated with better survival rates (Morioka, 2001).

The results of our study showed statistically significant falls in the A1C following iron and ESA treatment (mean 5.95% following iron and 5.41% following ESA) in the absence of a change in glycemic control. It showed that A1C can be unreliable and can fall following treatment with both iron and ESA therapy. (Sunil et al., 2010). Fluctuations of A1C that can occur in this patient group (patients with diabetes and CKD who were treated with iron or ESA therapy) so alternative methods for measuring glycemic control such as capillary glucose testing and CGM should be used, and therapy should not be based on the A1C value alone.

It has been shown that 62% of the population variance in HbA1c level is genetically determined (Jeffcoate, 2004).

(Inaba et al., 2007). Glycated albumin has been suggested as an alternative marker to represent glycemic control, as it was noted to be similar (in contrast to A1C, which was higher) in patients with iron deficiency and pre-ESA compared with patients post therapy.

It is known that glycation among various proteins is increased in diabetic patients compared with non-diabetic subjects. Currently, among these glycated proteins, glycated hemoglobin (HbA1C) is used as the gold standard index of glycemic control in clinical practice for diabetes treatment. However, HbA1C does not accurately reflect the actual status of glycemic control in some conditions where plasma glucose changes during short term, and in patients who have diseases such as anemia and variant hemoglobin. In comparison, another index of glycemic control, glycated albumin (GA), more accurately reflects changes in plasma glucose during short term and also postprandial plasma glucose. Although GA is not influenced by disorders of hemoglobin metabolism, it is affected by disorders of albumin metabolism. Some diseases and pathologival conditions where GA measurement is useful. These include the status of glycemic control changes during short term, diseases which cause postprandial hyperglycemia, iron deficiency anemia, pregnancy, chronic liver disease (liver cirrhosis), chronic renal failure (diabetic nephropathy), and variant hemoglobin (Masafumi and Soji, 2010).
This study managed to show that A1C values fell significantly both with iron and ESA. This change in A1C was independent of changes in glycemic control. Intravenous iron and ESA are increasingly common therapies used in the management of anemia in patients with CKD and diabetes. The present study has been able to confirm that reported changes in A1C following these treatments are independent of changes in glycemic control; therefore, caution is warranted in the interpretation of A1C and management of glycemia when based on A1C alone.

At a time when self monitoring of blood glucose is being discouraged, especially in non–insulin treated patients, regular capillary glucose measurements, and the concurrent use of CGM if available, seems essential in order to accurately assess glycemic control in this group of patients. (Simon et al., 2008).

This study showed no significant change occur in T. Protein, albumin, BUN, and creatinine levels among groups during course of treatment. Table (12,13,14,15) Fig (9,10,11,12). This study showed no significant value of duration of diabetes and duration of hemodialysis. Table (3) Fig (2).

Conclusion:-
A1c is the most widely accepted and used method of assessing chronic glycemia in patients with diabetes. This is study to showed that iron and ESA treatments result in a fall in A1C, which is independent of glycemic changes in patients with diabetes and CKD.

References:-
1. A1-Khoury(2007) : Characteristics of Anaemia Management in Patients with Chronic Kidney Disease Am J Kidney Dis, Vol.50, pp. 474-6
2. American Diabetes Association. (2016) : guidelines of diagnosis and screening of diabetes. diabetes care.
3. Brooks Ap I Metcalfe J I Day JL 1 Edwards MS .Iron deficiency and glycosylated haemoglobin A. Lancet1980; 2:141.
4. Goldstein DE, Little RR, Lorenz RA, Malone JL, Nathan D, Peterson CM, Sacks DB. Tests of glyemia in diabetes. Diabetes Care 2004;27:1761-1773
5. Gram Hansen pEIriksenJIMourits- Andersen T 1 OlesenL.Glycosylatedhaemoglobin (HbA1c) Bin iron- and vitamin B 12 deficiency. J Intern Med 1990; 227:133-136
6. Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, Murata Y, Kasayama S, KogaM. A1C but not serumglycated albumin is elevated in late preg-nancy owing to iron deficiency. DiabetesCare 2008;31:1945–1948
7. Herranz L, Grande C, Janez M. et al., (1999): Red blood cell auto-antibodies with a shortened erythrocyte life span as a cause of lack of relation between glycosylated hemoglobin and mean blood glucose levels in a woman with type 1 diabetes. Diabetes Care;22(12):2085–6.
8. Jeffcoate S (2004) : Diabetes control and complications: the role of glycedahemoglobin, 25 years on. Diabetic Med, 21:657–665.
9. Jiao Y, Okumiya T, Saibara T et al., (1998): Abnormally decreased HbA1c can be assessed with erythrocyte creatine in patients with a shortened erythrocyte age. Diabetes Care;21(10):1732–5.
10. kimCl Bullard KM I Herman WH I Beckles GL. Association between iron deficiency and Hballe levels among adults 2006
11. Kutter D and Thoma J (2006): Hereditary spherocytosis and other hemolytic anomalies distort diabetic control by glycatedoglobin. Clin Lab;52(9-10):477–81.
12. Liew CF and Cheah JS (2003): Hereditary spherocytosis, a pitfall in the assessment of glycaemic control. Singapore Med J;44(2):94–7.
13. Inaba M 1 OKuno S 1 Kumeda Y 1 Yamada S 1 Imanishi Y 1 Tabata T Okamura M 1 Okada T1 lshimura E1 Nishizawa Y. Glycated albumin is a better glycemic indicator than glycated hemoglobin Values in hemodialysis patients With diabetes :effect of anemia and erythropoietin injection . Jam Soc Nephrol2007; 18 :896-903
14. Lucia Del Vecchio*, Selena Longhi and Francesco Locatelli (2016): Safety concerns about intravenous iron therapy in patients with chronic kidney disease: Clin Kidney J doi: 10.1093/ckj/sfv142 Volume 94, Issue 3 April 2008 Pages 172–18
15. Lum G. (2010): Artefactually low hemoglobin A1c in a patient with hemolytic anemia. Lab Med;41(5):267–70.
16. M. Muñoz, J. A. García-Erce, S. Gómez-Ramírez, J. Comin and E (2008): Efficacy and safety of intravenous iron therapy: Vox Sanguinis, Pages 172 183.
17. Masafumi Koga and Soji Kasayama (2010): Clinical impact of glycated albumin as another glycemic control marker. Endocrinal journal; vol.57 No.9p:751-762
18. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909–913
19. Nakao T, Matsumoto H, Okada T, Han M, Iida H, Yoshino M, Shino T, Yamada C, Nagaoka Y. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826–830
20. National Collaborating Centre For Chronic Conditions Anemia management in Chronic Kidney disease (2006): national clinical guideline for management in adults and children. London: Royal College Of Physicians; 2006.
21. Ng JMI, Jennings PE, Laboi PI, Jayagopal V. Erythropoietin treatment significantly alters measured glycated haemoglobin (HbA1c). Diabet Med 2008;25:239–240
22. Nissenson AR, Strokos J. Iron deficiency in patients with renal failure. Kidney Int 1999;55:S18–S21
23. Osamu Takahashi, Andrew J. Farmer, FRCPet al., (2016): A1C to Detect Diabetes in Healthy Adults. Diabetes Care;33(9)
24. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–203
25. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A. Cost effectiveness of self-monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177–1180
26. Singh A, Szczek L, Tang K (2006): Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med;335:2085–98
27. SUNIL BHANDARI, STEPHEN L, ATKIN, ERIC S, KILPATRICK, et al (2010): The Effect of Iron and Erythropoietin Treatment on the A1C. Diabetes care 33(11):2310–3. DOI: 10.2337/dc10-0917 ·
28. Teehan G and Benz RL (2011): An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost. Anemia; 201:623-673.
29. Teehan, S., Krantz, W. A., Stone et al (1991) “Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients,” American Journal of Kidney Diseases, vol. 18, no. 1, pp. 50–59.
30. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003;26:1164–1169
31. Weykamp CW, Penders TI, Siebelder CW, et al., (1993): Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. ClinChem; 39(1):138–42.